Strand Therapeutics Announces Initial First-in-human Phase 1 Data for STX-001 in Patients with Advanced Solid Tumors at The 2025 ASCO Annual Meeting
'This is a transformative moment for Strand and for the field of synthetic mRNA therapeutics,' said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. 'The Phase 1 data for STX-001 provide early clinical validation of our platform."
Share
In the ongoing first-in-human Phase 1, open-label, dose-escalation clinical trial, STX-001 demonstrated a favorable safety profile and encouraging signs of anti-tumor activity as a monotherapy in patients with immune checkpoint inhibitor-refractory solid tumors, including melanoma and other solid tumor indications. As of the April 3rd, 2025 data cutoff, the trial had enrolled 22 patients across multiple sites in the United States and Australia. All patients were treated with STX-001 as a monotherapy (without combination with immune checkpoint inhibitors, etc.) with injections to surface accessible lesions.
The data will be presented at The 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago on June 1 by Sarina Piha-Paul, M.D., professor of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center.
'This investigational therapy has the potential to address an important unmet need in patients with checkpoint inhibitor-refractory advanced cancers,' said Dr. Piha-Paul. 'We're observing systemic immune activation and antitumor responses, including in non-injected lesions, across multiple tumor types, which is encouraging and supports continued evaluation.'
Key highlights from the Phase 1 trial include:
Preliminary Clinical Activity: Multiple RECIST responses were observed, including a confirmed complete response and multiple partial responses. Furthermore, there were multiple cases of prolonged disease stabilization.
Safety and Tolerability: STX-001 was well-tolerated up to 300 µg. Treatment-related adverse events were consistent with STX-001's intended mechanism of action of immune activation.
Pharmacodynamic Activity: Biomarker analysis confirmed dose-dependent increase in plasma IL-12 and IFN-γ, as well as infiltration of immune cells within the tumor microenvironment.
'This is a transformative moment for Strand and for the field of synthetic mRNA therapeutics,' said Jake Becraft, PhD, CEO and Co-founder of Strand Therapeutics. 'The Phase 1 data for STX-001 provide early clinical validation of our platform's ability to deliver programmable, tumor-localized immunotherapy safely and effectively. Our mRNA medicines as a therapeutic modality offer the potential capability to broaden pathways to treatment for patients while seamlessly integrating into the existing healthcare ecosystem.'
STX-001 encodes IL-12, an immunomodulatory protein, which the company has designed such that it can reprogram the tumor microenvironment and stimulate a systemic anti-tumor immune response. Unlike traditional mRNA therapies, Strand's approach uses self-replicating mRNA, ensuring localized and durable therapeutic activity.
The company is currently conducting dose expansion in the Phase 1 trial. Upon completion, the company plans to transition into a Phase 2 trial of STX-001 as a monotherapy. The company also plans to initiate dose escalation of STX-001 in combination with checkpoint inhibitors and expand into additional solid tumor indications. In addition, Strand is advancing a broader pipeline powered by the company's first-in-class cell-type specific mRNA engineering platform, including advancing STX-003, an intravenously administered version of STX-001, to patients in 2026.
ASCO Poster Presentation Information:
Abstract Title: Phase I dose escalation trial of STX-001, an LNP-encapsulated self-replicating mRNA expressing IL-12, in patients (pts) with advanced solid tumors.
Session Type: Poster
Date and Time: June 1, 9:00 AM-12:00 PM CDT
Abstract Number: 9556
Location: Hall A
Full abstract is available on the ASCO Annual Meeting Website.
The study, an open-label, dose escalation trial, evaluated the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of STX-001 in patients with advanced solid tumors. STX-001 was well-tolerated up to 300 µg, with dose-dependent and manageable treatment-related adverse events. Promising early clinical activity was observed, including multiple RECIST responses and durable disease stabilization. Findings support the further development of STX-001 as a monotherapy and in combination with checkpoint inhibitors for the treatment of solid tumors.
Additional Commentary
Professor Georgina Long AO, BSc, PhD, MBBS, FRACP, FAHMS, AAHMS, FAA, Medical Director of Melanoma Institute Australia (MIA), and Chair of Melanoma Medical Oncology and Translational Research at MIA and Royal North Shore Hospital, The University of Sydney: 'I am encouraged by this early data. While intratumoral therapies offer a promising approach by initiating immune activation at the injected tumor site, they have historically struggled to generate robust systemic responses. STX-001 may represent a meaningful step forward, with early clinical evidence showing cases of regression of non-injected lesions, a sign of systemic immune engagement.'
Tasuku Kitada, PhD, Co-Founder, President, and Head of R&D at Strand Therapeutics: 'Patients who are refractory to immune checkpoint inhibitors urgently need new treatment options. While IL-12 has long been recognized as a powerful immune stimulator, its clinical potential has been limited by toxicity, and to date, no IL-12–based therapies have been approved by the FDA. STX-001 is designed to overcome these challenges, delivering localized IL-12 expression to activate the tumor microenvironment and drive systemic immune responses, all while seeking to minimize toxicities. These early data suggest we may finally be able to realize the promise of IL-12 in cancer therapy.'
About STX-001
STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended period of time, directly injected into the tumor microenvironment in order to promote immune modulation and antitumor activity. The company received IND clearance from the U.S. Food and Drug Administration (FDA) in December 2023 to initiate a Phase 1/2 clinical trial for STX-001, and announced its first patient dosed just before the 2024 ASCO Annual Meeting. Additional study details can be found at clinicaltrials.gov, using identifier: NCT06249048.
About Strand Therapeutics
Strand Therapeutics is a clinical-stage biotechnology company developing programmable mRNA therapeutics to transform the treatment of cancer and other serious diseases. Founded by synthetic biology pioneers from MIT, Strand's proprietary platform integrates synthetic gene circuits with mRNA delivery to enable targeted, controlled, and intelligent therapies. The company is based in Boston, Massachusetts. For more information, visit www.strandtx.com. Follow us on LinkedIn and on X at @StrandTx.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
30 minutes ago
- Business Wire
Personalized Learning in High School Helps Prepare Students for the Workforce
LOS ANGELES--(BUSINESS WIRE)--Are employers settling for better-than-nothing applicants to fill their entry-level positions? In a recent J. Wallin Opinion survey of businesses large and small across the U.S., 43 percent said that they have lowered their hiring standards due to reduced skill levels – and of those, 57 percent feel it has negatively affected their business. 1 Since only 50 percent of high school seniors plan to go to a four-year college, high schools must prepare students for the workforce as well as post-secondary education Share 'We believe it's important that teens learn basic workplace skills to help them land and keep a job,' said Shellie Hanes, superintendent at Learn4Life, a network of public high schools that personalize learning to individual students' needs, strengths and goals. 'Since only 50 percent of high school seniors plan to go to a four-year college 2, high schools must prepare students for the workforce as well as post-secondary education.' While earning their diplomas, all Learn4Life students complete a 10-week professional skills course that has them exploring career goals and learning basic computing, resume preparation and interview etiquette. Once completed, students move on to workforce development activities with structured, hands-on experiences that allow them to discover career pathways, develop essential skills and transition smoothly into a career or higher education. August is Personal Learning Month, created to promote the idea of teaching students in the way each learns best, with opportunities to learn job and life skills that will serve them after high school. More than 90 percent of employers said that personalized learning would help produce better-prepared candidates for entry-level positions. 3 'Many students lacked organizational skills, struggled with grammar, had no idea how to fill out a job application, handle a job interview or understand the basics of appropriate work behavior,' Hanes added. 'We offer courses so teens can acquire the skills to succeed in whatever job they want to pursue. Plus, many graduate with industry-recognized certifications – saving them thousands of dollars and giving them an advantage over other recent grads.' Employers cite these basic skills that entry-level workers are least likely to have 4: Work ethic/dependability Time management Problem-solving skills People skills with other employees Interpersonal skills with clients Punctuality Leadership Hanes said Learn4Life addresses those skills and teaches students about workplace communication, career readiness, employability skills, leadership and even financial literacy. 'By developing a personalized learning plan for each student, we can help them grow in areas they are good at and spend a little extra time on the skills they're lacking,' she explained. 'Because they are regularly communicating directly with their teachers and school counselors, they become comfortable speaking with adults and responding to what is expected of them.' Students then can move on to a specific CTE pathway where they are introduced to workplace competencies and receive hands-on learning– with options like computer programming, foodservice, healthcare, construction, veterinary medicine, robotics, construction and cyber-security. They earn industry-recognized certifications so they can secure internships, apprenticeships or jobs. One student, Jackie R., had dropped out of school to take care of her two children. Fortunately, she found Learn4Life, where the flexibility and personalized support helped her catch up on credits. She started in a dual-enrollment certified nursing assistant (CNA) program, balancing hands-on clinicals, academic work and motherhood with the help of her teachers and a close-knit group of classmates. 'Before I came to this school, I never envisioned being anybody. And now I know I can be somebody,' Jackie said, smiling. Find out more about Learn4Life and its personalized learning model at If interested in additional insights from the national hiring survey, please contact Learn4Life. About Learn4Life Learn4Life is a network of nonprofit public high schools that provide students personalized learning, career training and life skills. Each school is locally controlled, tuition free and gives students the flexibility and one-on-one attention they need to succeed. Serving more than 64,000 students through a year-round program, we help them prepare for a future beyond high school. For more information, please visit 1 From Friday, May 16, through Monday, June 2, 2025, J. Wallin Opinion Research conducted an online survey of employers nationwide, plus an oversample in California. 2,000 employers were interviewed nationwide, plus an oversample to equal 450 within California. A survey of this size yields a margin of error of +/-2.2 percent (95 percent confidence interval) nationwide, and +/-4.6 percent within California. 2 This random double-opt-in survey of 2,000 Americans — 1,000 parents of public high school students and 1,000 recent public high school graduates (ages 18 and 19) — was commissioned by Learn4Life between June 17 and June 27, 2024. It was conducted by market research company Talker Research, whose team members are members of the Market Research Society (MRS) and the European Society for Opinion and Marketing Research (ESOMAR). 3 From Friday, May 16, through Monday, June 2, 2025, J. Wallin Opinion Research conducted an online survey of employers nationwide, plus an oversample in California. 2,000 employers were interviewed nationwide, plus an oversample to equal 450 within California. A survey of this size yields a margin of error of +/-2.2 percent (95 percent confidence interval) nationwide, and +/-4.6 percent within California. 4 From Friday, May 16, through Monday, June 2, 2025, J. Wallin Opinion Research conducted an online survey of employers nationwide, plus an oversample in California. 2,000 employers were interviewed nationwide, plus an oversample to equal 450 within California. A survey of this size yields a margin of error of +/-2.2 percent (95 percent confidence interval) nationwide, and +/-4.6 percent within California.
Business Wire
30 minutes ago
- Business Wire
Anoki Named 'Best Overall CTV Solution Provider' in 2025 MarTech Breakthrough Awards
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)-- Anoki, the pioneer in multimodal AI for Connected TV (CTV), today announced it has been named 'Best Overall CTV Solution Provider' in the 8th annual MarTech Breakthrough Awards, conducted by MarTech Breakthrough, a leading market intelligence organization that recognizes the world's most innovative marketing, sales, and advertising technology companies. The 2025 program attracted over 4,000 nominations from across the globe, with winners representing the most innovative solutions in the industry. This year's roster includes Adobe, HubSpot, Sprout Social, Cision, ZoomInfo, Optimizely, Sitecore, and other top technology leaders, alongside in-house martech innovations from companies such as Verizon and Capital One. Anoki earned this recognition for its flagship ContextIQ platform and interactive AI copilot, the industry's first end-to-end multimodal AI solution for scene-level contextual video intelligence in CTV. By simultaneously analyzing signals that include video, audio, dialogue, sentiment, and emotion, ContextIQ's multimodal AI contextual video intelligence enables advertisers to match their messages with precise moments in premium CTV content, ensuring brand suitability, boosting viewer engagement, and safeguarding privacy by focusing on content relevance rather than personal data. The interactive copilot puts campaign planning at advertisers' fingertips with brand suitability filters, customized scene recommendations, viewership forecasts, and previews of specific scenes where your ads can run. 'Anoki's platform represents a paradigm shift in how brands connect with audiences,' said Steve Johansson, Managing Director at MarTech Breakthrough. 'In the evolving Connected TV landscape, Anoki stands apart through its application of agentic multimodal AI, fundamentally transforming the advertising experience for advertisers, viewers and publishers through contextual targeting at the scene-level – and at scale.' This latest honor follows a period of significant momentum for Anoki, including its integration with Magnite's SpringServe platform to bring scene-level targeting tools to market, and its planned collaboration with The Trade Desk's Ventura TV OS to power AI-native FAST experiences for OEM partners. These developments continue Anoki's mission to create a better CTV ecosystem for advertisers, publishers and viewers alike. 'Contextual intelligence creates a virtuous cycle where viewers see more relevant ads that respect their privacy, advertisers gain transparency and stronger performance, and content creators secure sustainable funding for quality programming,' said Raghu Kodige, CEO and Co-Founder of Anoki. 'Being named Best Overall CTV Solution Provider validates our mission and the real-world results we're driving for the CTV ecosystem.' Anoki's AI leadership is spearheaded by Susmita Ghose, Co-Founder and Head of AI, recently honored in the inaugural 100 Women in AI awards. 'With ContextIQ, we capture the full sensory context of every scene—from visuals and music to sentiment and dialogue—so ads are placed in the most meaningful moments,' Ghose said. 'It's how we ensure value without compromise for advertisers, publishers, and viewers alike.' The MarTech Breakthrough Awards celebrate excellence in categories spanning marketing automation, AdTech, SalesTech, analytics, content marketing, and more. Winners are selected for their innovation, performance, and impact on the global marketing technology landscape. About Anoki Anoki is a pioneering AI company revolutionizing the world of connected TV (CTV), from content discovery to advertising and engagement. Anoki empowers content partners, CTV platforms, and advertisers to connect with their target audiences with unparalleled precision for maximum impact. Our suite of innovative solutions – LiveTVx (AI-enhanced native FAST service), ContextIQ (AI-powered contextual CTV advertising), and AdMagic (GenAI for video ad creation and personalization) – harnesses the power of cutting-edge AI to deliver hyper-personalized viewing experiences that seamlessly integrate high-quality content and dynamically customized ads that resonate deeply with viewers. Learn more at About MarTech Breakthrough Part of Tech Breakthrough, MarTech Breakthrough is a leading market intelligence and recognition platform for global technology innovation and leadership, devoted to honoring excellence in marketing, ad, and sales technology companies, products, and people. Visit
Business Wire
30 minutes ago
- Business Wire
Unanimous AI Selected for Air Force Funding to Build Hyperchat AI™ Technology Into Microsoft Teams ® to Optimize Collaboration
ARLINGTON, Va.--(BUSINESS WIRE)--Today, Unanimous AI announced it has been selected for a Tactical Funding Increase (TACFI) contract with AFWERX, the innovation arm of the Department of the Air Force and a directorate within the Air Force Research Laboratory. The funding of up to $1M will be used to support a software development effort to incorporate Unanimous' Hyperchat AI ™ technology into Microsoft Teams ® in order to optimize large-scale communication, collaboration, and collective intelligence across very large organizations. Modeled on the biological principle of swarm intelligence, Hyperchat AI ™ employs a swarm ® of AI agents that enable large, networked teams (20 to 250 members) to hold productive real-time conversations by text, voice, or video conference. Using this patented agentic technology, teams of unprecedented size can collaborate conversationally in real-time to share information, assess risks, debate alternatives, brainstorm ideas, prioritize options, and converge on optimized solutions. Despite advancements in real-time messaging and video-conferencing over the last decade, productive conversations generally fall apart in groups larger than 8 to 10 people. Hyperchat AI overcomes this longstanding problem to enable groups of potentially any size to engage in productive real-time discussions that leverage their combined knowledge, wisdom, and insight. Hyperchat AI technology has been validated through a series of rigorous studies performed with researchers at Carnegie Mellon University. These studies show that real-time conversations using Hyperchat AI technology makes large teams more effective and efficient, and significantly amplifies the accuracy and intelligence of the conclusions reached. Hyperchat technology is currently available in a cloud-based platform from Unanimous AI called Thinkscape® that is already being used by large corporations and organizations around the world. Now, by integrating the technology directly into Microsoft Teams, Hyperchat AI will be accessible at scale across the US Air Force. 'While most AI companies are rushing to replace people, Unanimous AI has spent years optimizing how AI can weave human teams into superintelligent systems,' said Dr. Louis Rosenberg, CEO and Chief Scientist of Unanimous AI. 'Our new Hyperchat AI™ technology uses a swarm® of AI agents to optimally interconnect large teams through natural real-time discussions, debates, brainstorms and deliberations, leading to smarter, faster, and more accurate outcomes.' How it works: Hyperchat AI works by dividing a large group into parallel subgroups, each sized for thoughtful deliberation. The patented Hyperchat AI engine then uses a dynamic network of Conversational Surrogate AI Agents to intelligently share content among the subgroups in real-time. This allows human expertise, insight, and situational awareness to rapidly propagate across the network, enabling distributed teams of specialists, stakeholders, and subject-matter experts to efficiently converge on smarter, faster, and more accurate solutions (Hyperchat AI diagram). 'Hyperchat AI technology is a breakthrough in collaboration, communication, and collective intelligence,' says David Baltaxe, President of Unanimous AI. 'We are excited for the opportunity to work with the U.S. Air Force to build Hyperchat AI into Microsoft Teams deployments. This will enable large, distributed teams to solve critical problems more effectively. Our goal is to empower large organizations to collaborate so seamlessly, they become a Collective Superintelligence.' Unanimous AI is a leading developer of AI tools that optimize collaboration across large, networked teams, amplifying intelligence while keeping humans in the loop. The company's cloud-based platforms, Swarm® and Thinkscape®, have been used by high profile customers around the world from Fortune 500 corporations to major-league sports teams, hedge funds, the Department of Energy, and the United Nations. The views expressed are those of the author and do not necessarily reflect the official policy or position of the Department of the Air Force, the Department of Defense, or the U.S. government. About Unanimous AI Unanimous AI develops technologies that make human teams significantly smarter. Modeled on the dynamics of biological swarms, their patented Swarm AI ® and Hyperchat AI ™ technologies can turn networked teams into a Collective Superintelligence. Their award-winning software platforms, Swarm ® and Thinkscape ®, have been validated by numerous academic studies and are currently used by large organizations around the world. For more information, visit: About AFRL The Air Force Research Laboratory, or AFRL, is the primary scientific research and development center for the Department of the Air Force. AFRL plays an integral role in leading the discovery, development and integration of affordable warfighting technologies for our air, space and cyberspace forces. With a workforce spanning across nine technology areas and 40 other operations around the globe, AFRL provides a diverse portfolio of science and technology ranging from fundamental to advanced research and technology development. For more information, visit About AFWERX As the innovation arm of the DAF and a directorate within the Air Force Research Laboratory, AFWERX brings cutting-edge American ingenuity from small businesses and start-ups to address the most pressing challenges of the DAF. AFWERX employs approximately 370 military, civilian and contractor personnel at four hubs and sites executing an annual $1.4 billion budget. Since 2019, AFWERX has awarded over 10,400 contracts worth more than $7.24 billion to strengthen the U.S. defense industrial base and drive faster technology transition to operational capability. For more information, visit:
